China approves Sinovac Biotech Covid-19 vaccine for general public use | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
China approves Sinovac Biotech Covid-19 vaccine for general public use

Coronavirus chronicle

Reuters
06 February, 2021, 03:35 pm
Last modified: 06 February, 2021, 03:41 pm

Related News

  • Chinese man jailed for secretly drugging colleague with 'truth serum', leaving him hospitalised
  • After India's visa restriction, China's Kunming is drawing Bangladeshi patients
  • Rubio to meet China's foreign minister in Malaysia as US-Chinese tensions mount
  • China, Canada commit to deeper engagement with Bangladesh on trade, humanitarian assistance
  • Tariffs drive US clothing imports from China to 22-year low in May

China approves Sinovac Biotech Covid-19 vaccine for general public use

It marks the second Covid-19 vaccine green-lighted for public use in China

Reuters
06 February, 2021, 03:35 pm
Last modified: 06 February, 2021, 03:41 pm
FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo
FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo

Sinovac Biotech said on Saturday that its unit's Covid-19 vaccine has been formally approved for use by the general public by China's medical products regulator.

It marks the second Covid-19 vaccine green-lighted for public use in China, after a shot developed by a Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.

Prior to the approvals, both vaccines have already been used in China's vaccination program mainly targeting key groups deemed to be at higher risk of exposure to the virus.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorizations for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release.

The approval is based on the two-month results from late-stage clinical trials overseas, from which the final analysis data has not yet been obtained, Sinovac said.

China / Sinovac / COVID-19 / Vaccine / approve / general use

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • RAB Director General AKM Shahidur Rahman speaks at the press briefing on a fake bomb threat on Biman Bangladesh flight on Saturday, 12 July 2025. Photo: TBS
    Mother faked bomb threat on Biman flight to stop married son from flying to Kathmandu with girlfriend: RAB
  • Jubo Dal President Abdul Monayem Munna and other leaders of BNP's affiliate wings at a press conference at Nayapaltan office in Dhaka on Saturday. Photo: TBS
    Mitford murder: Jubo Dal accuses police of intentional neglect, demands arrest of ‘3 real killers’
  • Caught between a rock and a hard place. Cartoon: TBS
    Bangladesh's Trump tariff dilemma: Caught between a rock and a hard place?

MOST VIEWED

  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods
  • Screengrab blurred
    Killers bash in head of man with rock, stomp body with perverse pleasure
  • How tender rules and a lone bidder stall a $2.5b power plant
    How tender rules and a lone bidder stall a $2.5b power plant
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case
  • Photo: UNB
    WHO's Saima Wazed Putul 'placed on indefinite leave' amid corruption allegations: Health Policy Watch
  • After India's visa restriction, China's Kunming is drawing Bangladeshi patients
    After India's visa restriction, China's Kunming is drawing Bangladeshi patients

Related News

  • Chinese man jailed for secretly drugging colleague with 'truth serum', leaving him hospitalised
  • After India's visa restriction, China's Kunming is drawing Bangladeshi patients
  • Rubio to meet China's foreign minister in Malaysia as US-Chinese tensions mount
  • China, Canada commit to deeper engagement with Bangladesh on trade, humanitarian assistance
  • Tariffs drive US clothing imports from China to 22-year low in May

Features

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

20h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Home Affairs Advisor calls on everyone to come forward and stop violence

Home Affairs Advisor calls on everyone to come forward and stop violence

1h | TBS Today
More than a thousand layoffs at once in US government agencies

More than a thousand layoffs at once in US government agencies

1h | TBS World
Bangladesh-US tariff talks unresolved

Bangladesh-US tariff talks unresolved

3h | TBS Stories
Putul on indefinite leave after four months in 2 ACC cases

Putul on indefinite leave after four months in 2 ACC cases

3h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net